Top 5 Approved Systemic Lupus Erythematosus Drugs
Published:
Systemic lupus erythematosus (SLE) drugs are a class of therapeutic agents designed to manage the complex and multifaceted manifestations of SLE, a chronic autoimmune disease characterized by abnormal immune system activation and the production of autoantibodies against healthy tissues. By targeting different components of the immune response, these therapies help suppress excessive inflammation, reduce autoimmune activity, prevent disease flares, and minimize progressive damage to organs and tissues affected by the disease.
The therapeutic potential of SLE drugs has gained substantial attention due to the systemic nature of the disease and its ability to affect multiple organs, including the skin, joints, kidneys, cardiovascular system, and nervous system. These therapies offer significant clinical benefits, such as improved disease control, reduction in disease activity and flares, prevention of organ damage, and enhanced long-term patient outcomes. Consequently, increasing disease awareness and the need for more effective and targeted treatment options have driven continued interest among pharmaceutical companies, academic institutions, and healthcare organizations.
The domain is further supported by rising investments, strategic partnerships, licensing agreements, clinical development initiatives, and regulatory advancements aimed at accelerating the development of innovative SLE therapies. Collectively, these advancements position SLE drugs as a rapidly evolving therapeutic category, with the potential to significantly improve treatment outcomes and address the substantial unmet medical needs associated with systemic lupus erythematosus.
Roots Analysis has conducted an exhaustive study of the systemic lupus erythematosus drugs featuring the current market landscape and future opportunities for developers engaged in healthcare, over the span of next 9 years.
Key Five Approved Systemic Lupus Erythematosus Drugs
1. Acthar Gel (Repository Corticotropin Injection)
2. Belimumab (Benlysta / BEL114333 / GSK1550188)
3. Telitacicept (RC18)
4. Anifrolumab (Saphnelo / MEDI-546)
5. Plaquenil® (Hydroxychloroquine Sulfate)
The figure below highlights approved systemic lupus erythematosus drugs:

Interested in exploring all 130+ systemic lupus erythematosus drugs, along with their recent initiatives?
Discover Below the Details on 5 Approved Systemic Lupus Erythematosus Drugs
Let us dive deep into the details of the 5 approved systemic lupus erythematosus drugs. It is essential to note that the selection of approved systemic lupus erythematosus drugs can differ substantially according to the defined criteria.
1. Acthar Gel (Repository Corticotropin Injection)
The section provides information on various parameters, with details on list of developer, type of molecule, type of therapy, route of administration, drug frequency and patient type.
- Developer: Mallinckrodt Pharmaceuticals
- Type of Molecule: Biologic
- Type of Therapy: Monotherapy
- Route of Administration: Subcutaneous
- Drug Frequency: Multiple
- Patient Type: Adult, Older Adult
To know more about the recent initiatives of Acthar Gel (Repository Corticotropin Injection) and other SLE drugs, access full report.
2. Belimumab (Benlysta / BEL114333 / GSK1550188)
The section provides information on various parameters, with details on list of developer, type of molecule, type of therapy, route of administration, drug frequency and patient type.
- Developer: GSK
- Type of Molecule: Biologic
- Type of Therapy: Combination
- Route of Administration: Intravenous and Subcutaneous
- Drug Frequency: Multiple
- Patient Type: Adult, Older Adult
Recent Developments
In August 2026, Sandoz entered into a collaboration with Henlius with an aim to develop biosimilars for belimumab. Sandoz received exclusive commercialization rights outside China for the proposed belimumab biosimilar.
To know more about the recent initiatives of Belimumab (Benlysta / BEL114333 / GSK1550188) and other SLE drugs, access full report.
3. Telitacicept (RC18)
The section provides information on various parameters, with details on list of developer, type of molecule, type of therapy, route of administration, drug frequency and patient type.
- Developer: RemeGen
- Type of Molecule: Biologic
- Type of Therapy: Monotherapy
- Route of Administration: Subcutaneous
- Drug Frequency: Multiple
- Patient Type: Adult, Older Adult
Recent Developments
In June 2026, Telitacicept received NMPA approval in China for Sjogren's disease, expanding its autoimmune disease footprint across multiple regions.
To know more about the recent initiatives of Telitacicept (RC18) and other SLE drugs, access full report.
4. Anifrolumab (Saphnelo / MEDI-546)
The section provides information on various parameters, with details on list of developer, type of molecule, type of therapy, route of administration, drug frequency and patient type.
- Developer: AstraZeneca
- Type of Molecule: Biologic
- Type of Therapy: Combination
- Route of Administration: Intravenous
- Drug Frequency: Multiple
- Patient Type: Adult, Older Adult
Recent Developments
In April 2026, the FDA approved Saphnelo for once-weekly subcutaneous biologics self-administration through an autoinjector (Saphnelo Pen) for adults with SLE receiving standard therapy.
To know more about the recent initiatives of Anifrolumab (Saphnelo / MEDI-546) and other SLE drugs, access full report.
5. Plaquenil® (Hydroxychloroquine Sulfate)
The section provides information on various parameters, with details on list of developer, type of molecule, type of therapy, route of administration, drug frequency and patient type.
- Developer: Sanofi
- Type of Molecule: Small Molecule
- Type of Therapy: Monotherapy
- Route of Administration: Oral
- Drug Frequency: Multiple
- Patient Type: Adult, Older Adult
To know more about the recent initiatives of Plaquenil® (Hydroxychloroquine Sulfate) and other SLE drugs, access full report.
What About Other Systemic Lupus Erythematosus Drugs Around the World?
The above article features the systemic lupus erythematosus drugs selected from a pool of over 130 systemic lupus erythematosus drugs that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources:
- https://www.sandoz.com/sandoz-announces-strategic-collaboration-henlius-10-biosimilars-further-expanding-industry-leading/
- https://ir.vorbio.com/news-releases/news-release-details/telitacicept-receives-nmpa-approval-treatment-sjogrens-disease
- https://www.astrazeneca.com/media-centre/press-releases/2026/saphnelo-self-administration-approved-in-the-US.html